I AM ALS responds to Amylyx Pharmaceuticals announcement on the ALS PHOENIX AMX0035 trial results (RELYVRIO®)

1200 Pennsylvania Ave NW #14135

Washington, DC 20044

FOR IMMEDIATE RELEASE

MEDIA CONTACT:
Shawna N. Prince
Director of Communications & Marketing
872-529-1873
Shawna@iamals.org

I AM ALS responds to Amylyx Pharmaceuticals announcement on the ALS PHOENIX AMX0035 trial results (RELYVRIO®)

(March 8, 2024, Washington, D.C.) I AM ALS is incredibly disappointed to learn of the results from the Phase III clinical trial for RELYVRIO®. On Friday, March 8, 2024, Amylyx Pharmaceuticals announced that the PHOENIX trial did not meet statistical significance for its primary or secondary endpoints.

As a movement of individuals affected by ALS, we share in the grief and emotion rippling through the community.

“I AM ALS advocated for approval of Relyvrio due to survival benefit data from their Phase II trial and in a landscape where safe therapies to reverse or delay progression remain desperately needed,” said Brian Wallach, I AM ALS Co-founder. “Now that the Phase III trial failed, we are grateful to Amylyx for their transparency and look forward to quick action in light of the new data.”

We will continue to utilize both the evidence and the desire of the ALS community in formulating our advocacy positions. Today’s announcement further validates the importance of flexibility as well as the need for quick and innovative research; federal and private sector investments; and speed to drive knowledge – both successes and failures – with the ultimate goal of effective therapies for the devastating, currently 100% fatal, ALS.

We appreciate Amylyx’s patient-centered approach and are grateful to every trial participant for their contributions.

###

About I AM ALS

I AM ALS is a patient-centric movement revolutionizing how to end disease. The nonprofit provides critical support and resources to people with ALS, caregivers, and loved ones. We empower advocates to raise awareness and lead the movement against ALS in driving the development of treatments and cures. Founded in 2019 by husband and wife team Brian Wallach and Sandra Abrevaya, I AM ALS was born out of their desire to rewrite the ALS story for Brian and the tens of thousands of other people with ALS. Learn more at iamals.org.